Company intelligence / Profile preview

PDL BioPharma

Incline Village / Incline Reno area / Mountain View CA historically, Nevada, United Statespdl.com ↗

Ownership: Private
Development stage: Commercial

Overview

PDL BioPharma was a pioneer in the humanization of monoclonal antibodies and generated significant revenue through royalties on blockbuster biologics such as trastuzumab, bevacizumab, and palivizumab. The company spun out its drug development activities into Facet Biotech in 2008 and focused on managing intellectual property assets until it entered liquidation effective January 2021. Its legacy includes enabling key therapeutic antibodies now marketed by major pharmaceutical companies.

Therapeutic areas: OncologyImmunologyNeurologyInfectious Diseases
Modalities: Monoclonal antibodySmall moleculeRecombinant protein
Industry: Drug Discovery Services

Partnerships

Roche/Hoffmann-La RocheGenentechSandoz/NovartisYamanouchi Pharmaceutical Co.Kanebo Ltd.Biogen Idec/AbbVie for Facet/daclizumab MS program

Beyond the preview

Go deeper on PDL BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PDL BioPharma.

Explore the full profile